Clinical Trials
54 trialsNivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
LIMIT
Abramson Cancer Center at Penn Medicine
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
CPIT001
Hackensack Meridian Health
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
NEPI
University Hospital, Essen
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
M.D. Anderson Cancer Center
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
H. Lee Moffitt Cancer Center and Research Institute
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
GlitIpNi
Universitair Ziekenhuis Brussel
Parpvax
University of Pennsylvania
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
CRIRIN
University Hospital, Strasbourg, France
CHOPIN
Leiden University Medical Center
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
University of Michigan Rogel Cancer Center
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
NSCLC
University of California, San Diego
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
University of Wisconsin, Madison
LAPTOP
Herlev Hospital
DONIMI
The Netherlands Cancer Institute
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Sarcoma Oncology Research Center, LLC
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
MARIANE
The Netherlands Cancer Institute
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
M.D. Anderson Cancer Center
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
QUAD01
University of Pittsburgh
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
IMCISION
The Netherlands Cancer Institute
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Weill Medical College of Cornell University
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Herlev Hospital
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
PRIME-HCC
Imperial College London
CRIMI
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CHARLI
Melanoma and Skin Cancer Trials Limited
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
University of Louisville
Study to Nivolumab Following Preoperative Chemoradiotherapy
National Cancer Center Hospital East
RADVAXâ„¢: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
Abramson Cancer Center at Penn Medicine
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
California Pacific Medical Center Research Institute
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
Institut Claudius Regaud
Doxycycline, Temozolomide and Ipilimumab in Melanoma
M.D. Anderson Cancer Center
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
NYU Langone Health
Mel62; 6PAC
University of Virginia
A Phase I/II Study of Intratumoral Injection of SD-101
Stanford University
ipniv
Universitair Ziekenhuis Brussel
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center